Pharmafile Logo
Pharmafocus logo
Advanced Search
test_results

The power of PrEP

August 8, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, PrEP, high court, lifestyle drug

Many among the general public may not have heard about PrEP, or pre-exposure prophylaxis, before last week when a high …

Feature
indiaflag

Opdivo and Keytruda set for India launches by end of year

August 8, 2016
Sales and Marketing India, keytruda, launch, opdivo

Indian cancer patients could be set to receive two of the world’s leading oncology drugs, MSD’s Keytruda and Bristol-Myers Squibb’s …

News
4741451457_6344b99835_z_-_copy

‘Game changer’ asthma pill sees significant reduction in severe symptoms

August 8, 2016
Research and Development, Sales and Marketing Fevipiprant, Novartis, asthma, university of Leicester

A study at the University of Leicester has found that Fevipiprant (QAW039), the first new asthma pill for nearly 20 …

News
merck_and_co

MSD files Lantus biosimilar with FDA

August 8, 2016
Sales and Marketing FDA, Lantus, MK-1293, MSD, application, biosimilar

MSD, known as Merck in the US and Canada, has filed a new drug application with the US Food and …

News
opdivo_1

Shock for BMS as Opdivo misses goal in late-stage lung cancer trial

August 5, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo

Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

August 5, 2016
Medical Communications, Research and Development Actavis, Bioelectronics, CDF, Celgne, EMA, GSK, GlaxoSmithKline, Innovate UK, Medivation, NICE, Novartis, Roche, Sanofi, Teva, appointments, apremilast, biog, breast cancer, brexit, google, pharmaceutical industry, rheumatoid arthritis, sarilumab, top ten

It’s Friday, and we’ve seen some big developments in the industry’s headlines throughout the week, from news of Glaxo-Smith-Kilne’s new …

News

Novo Nordisk diabetes drug Victoza fails to reduce heart failure risk

August 5, 2016
Medical Communications, Research and Development Eli Lily, Novo Nordisk, Victoza, diabetes, heart failure

Novo Nordisk’s diabetes drug Victoza (liraglutide), which was found to cut cardiovascular risks in sufferers of heart disease, has failed …

News

Majority of US patients’ groups supporting pharma against Medicare reforms received industry funding, claims report

August 5, 2016
Medical Communications, Research and Development medicare reform, patients' groups, public citizen

An overwhelming majority of US patients’ groups who supported the pharmaceutical industry in opposing Medicare part B pricing reforms receive …

News
regeneron

Eylea sales jump helps boost Regeneron in Q2 results

August 5, 2016
Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results

Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …

News
novartis_iobmr

NICE recommends Cosentyx in ankylosing spondylitis

August 4, 2016
Research and Development, Sales and Marketing Cosentyx, NICE, Novartis, ankylosing spondylitis

Novartis has announced that the National Institute for Health and Care Excellence (NICE) has recommended Cosentyx (secukinumab) to treat adults …

News
mr058666-web

Merck Q2 results beat analyst estimates

August 4, 2016
Medical Communications, Sales and Marketing Merck, financial results

Germany pharmaceutical firm Merck has announced its fiscal results for Q2 2016, beating analyst estimates with earnings before interest, taxes, …

News
20160803-zika-dna-vaccine

NIH launches test of investigational human Zika vaccine

August 4, 2016
Research and Development Vaccine, Zika virus

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has begun the clinical …

News
fda2outsideweb

FDA determines Xiamen Origin Biotech wilfully lied to inspectors and customers

August 4, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Xiamen Origin Biotech

The US Food and Drug Administration (FDA) carried out an inspection of Chinese drug manufacturer  Xiamen Origin Biotech, finding the …

News
adaptimmune_lab_scientists_growing_research_cells_jpg-web

Bad news for Adaptimmune as partial clinical hold placed on T-cell oncology trial

August 4, 2016
Research and Development Adaptimmune, T cell, oncology, t-cell

Adaptimmune Therapeutics has received notice from the US Food and Drug Administration (FDA) that a partial clinical hold has been …

News

American pharmacy adds 35 products to list of excluded drugs

August 4, 2016
Sales and Marketing Drug pricing, cvs health, excluded drugs, hyperinflationary

American pharmacy chain CVS Health has added 35 products to its list of excluded drugs and will not cover certain …

News
roche_south

Roche cuts ties with Inovio in hepatitis B development

August 3, 2016
Research and Development Inovio, Roche, hepatitis B

Inovio Pharmaceuticals has announced that it will independently continue development of hepatitis B immunotherapy, INO-1800, after Swiss drugmaker Roche issued …

News
biogen_austria_238

Takeover rumours send Biogen’s stock soaring

August 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Biogen, MSD, rumours, takeover

Rumours have begun to circulate that companies including MSD and Allergan are plotting a takeover bid for Biogen, after a …

News
celgene_1_02

Celgene’s Otezla approved for NHS use

August 3, 2016
Research and Development, Sales and Marketing Celgene, NHS, NICE, apremilast

NICE has published draft guidance recommending the use of Celgene’s Otezla (apremilast) for use on the NHS for treatment of …

News
teva_copy

Teva completes $40 billion acquisition of Actavis Generics

August 3, 2016
Research and Development, Sales and Marketing Actavis, Allergan, Teva, acqusition, generics

Teva has announced that it has completed its acquisition of Actavis Generics, a subsidiary of Allergan, in a transaction valued …

News
merck_incweb

MSD scores EU approval for Keytruda in lung cancer

August 3, 2016
Research and Development, Sales and Marketing EU, MSD, Merck, approval, keytruda, lung cancer

MSD, called Merck in the US and Canada, has announced that the European Commission has approved Keytruda (pembrolizumab) for patients …

News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026